-Reuters
Keybanc Maintains Overweight on Colfax, Lowers Price Target to $52
Keybanc analyst Jeffrey Hammond maintains Colfax (NYSE:CFX) with a Overweight and lowers the price target from $60 to $52.
Related Posts
HOOKIPA Pharma Announces FDA Accepts Co.’s Investigational New Drug Application For HB-300 For The Treatment Of Metastatic Castration-resistant Prostate Cancer
Novel arenaviral immunotherapy is directed against the prostate cancer targets PAP and PSA; Phase 1/2 trial to commence by early 2023
Drug Master File (DMF) accepted to support future FDA submissions
Piper Sandler Maintains Overweight on Phillips 66, Lowers Price Target to $137
Piper Sandler analyst Ryan Todd maintains Phillips 66 (NYSE:PSX) with a Overweight and lowers the price target from $155 to $137.